The efficacy of chemoradiation therapy in HIV seropositive patients with squamous cell carcinoma of the anus

Jonathan Efron, A. J. Pikarsky, P. Gervaz, G. Locker, E. G. Weiss, S. D. Wexner, J. J. Nogueras

Research output: Contribution to journalArticle

Abstract

Objective. The aim was to assess the efficacy of chemoradiation therapy for squamous cell carcinoma of the anal canal in HIV seropositive patients. Patients and methods. A retrospective review of all patients with squamous cell carcinoma of the anus treated primarily with combined chemotherapy (5-fluorouracil and mitomycin) and radiotherapy or local excision was undertaken comparing HIV seropositive to HIV seronegative patients. Results. Thirteen HIV seronegative patients were compared with 6 HIV seropositive patients. The HIV positive group included a higher proportion of males and a significantly greater history of prior treatment for condyloma. There was no difference in the median radiation dose (5020 cGy vs 4500 cGy, P = 0.10). There was a trend towards higher local tumour recurrence in the HIV seropositive patients although this was not statistically significant (30% vs 66%). The CD4 count of HIV positive patients did not correlate either with their ability to complete the prescribed treatment regimen or with subsequent recurrence. Conclusion. Combined chemoradiation is feasible in HIV positive patients, however, local recurrence rates in HIV positive patients may be higher. Tolerance of this therapy in HIV seropositive patients or recurrence after therapy are not related to the patient's CD4 cell count.

Original languageEnglish (US)
Pages (from-to)402-405
Number of pages4
JournalColorectal Disease
Volume3
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Anal Canal
Squamous Cell Carcinoma
HIV
Therapeutics
Recurrence
CD4 Lymphocyte Count
Mitomycin
Fluorouracil
Radiotherapy
Radiation

Keywords

  • Anal carcinoma
  • Anus
  • Chemoradiation
  • HIV
  • HIV seropositive
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The efficacy of chemoradiation therapy in HIV seropositive patients with squamous cell carcinoma of the anus. / Efron, Jonathan; Pikarsky, A. J.; Gervaz, P.; Locker, G.; Weiss, E. G.; Wexner, S. D.; Nogueras, J. J.

In: Colorectal Disease, Vol. 3, No. 6, 2001, p. 402-405.

Research output: Contribution to journalArticle

Efron, Jonathan ; Pikarsky, A. J. ; Gervaz, P. ; Locker, G. ; Weiss, E. G. ; Wexner, S. D. ; Nogueras, J. J. / The efficacy of chemoradiation therapy in HIV seropositive patients with squamous cell carcinoma of the anus. In: Colorectal Disease. 2001 ; Vol. 3, No. 6. pp. 402-405.
@article{79af878c8eeb46cb909c373a10878128,
title = "The efficacy of chemoradiation therapy in HIV seropositive patients with squamous cell carcinoma of the anus",
abstract = "Objective. The aim was to assess the efficacy of chemoradiation therapy for squamous cell carcinoma of the anal canal in HIV seropositive patients. Patients and methods. A retrospective review of all patients with squamous cell carcinoma of the anus treated primarily with combined chemotherapy (5-fluorouracil and mitomycin) and radiotherapy or local excision was undertaken comparing HIV seropositive to HIV seronegative patients. Results. Thirteen HIV seronegative patients were compared with 6 HIV seropositive patients. The HIV positive group included a higher proportion of males and a significantly greater history of prior treatment for condyloma. There was no difference in the median radiation dose (5020 cGy vs 4500 cGy, P = 0.10). There was a trend towards higher local tumour recurrence in the HIV seropositive patients although this was not statistically significant (30{\%} vs 66{\%}). The CD4 count of HIV positive patients did not correlate either with their ability to complete the prescribed treatment regimen or with subsequent recurrence. Conclusion. Combined chemoradiation is feasible in HIV positive patients, however, local recurrence rates in HIV positive patients may be higher. Tolerance of this therapy in HIV seropositive patients or recurrence after therapy are not related to the patient's CD4 cell count.",
keywords = "Anal carcinoma, Anus, Chemoradiation, HIV, HIV seropositive, Squamous cell carcinoma",
author = "Jonathan Efron and Pikarsky, {A. J.} and P. Gervaz and G. Locker and Weiss, {E. G.} and Wexner, {S. D.} and Nogueras, {J. J.}",
year = "2001",
doi = "10.1046/j.1463-1318.2001.00281.x",
language = "English (US)",
volume = "3",
pages = "402--405",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The efficacy of chemoradiation therapy in HIV seropositive patients with squamous cell carcinoma of the anus

AU - Efron, Jonathan

AU - Pikarsky, A. J.

AU - Gervaz, P.

AU - Locker, G.

AU - Weiss, E. G.

AU - Wexner, S. D.

AU - Nogueras, J. J.

PY - 2001

Y1 - 2001

N2 - Objective. The aim was to assess the efficacy of chemoradiation therapy for squamous cell carcinoma of the anal canal in HIV seropositive patients. Patients and methods. A retrospective review of all patients with squamous cell carcinoma of the anus treated primarily with combined chemotherapy (5-fluorouracil and mitomycin) and radiotherapy or local excision was undertaken comparing HIV seropositive to HIV seronegative patients. Results. Thirteen HIV seronegative patients were compared with 6 HIV seropositive patients. The HIV positive group included a higher proportion of males and a significantly greater history of prior treatment for condyloma. There was no difference in the median radiation dose (5020 cGy vs 4500 cGy, P = 0.10). There was a trend towards higher local tumour recurrence in the HIV seropositive patients although this was not statistically significant (30% vs 66%). The CD4 count of HIV positive patients did not correlate either with their ability to complete the prescribed treatment regimen or with subsequent recurrence. Conclusion. Combined chemoradiation is feasible in HIV positive patients, however, local recurrence rates in HIV positive patients may be higher. Tolerance of this therapy in HIV seropositive patients or recurrence after therapy are not related to the patient's CD4 cell count.

AB - Objective. The aim was to assess the efficacy of chemoradiation therapy for squamous cell carcinoma of the anal canal in HIV seropositive patients. Patients and methods. A retrospective review of all patients with squamous cell carcinoma of the anus treated primarily with combined chemotherapy (5-fluorouracil and mitomycin) and radiotherapy or local excision was undertaken comparing HIV seropositive to HIV seronegative patients. Results. Thirteen HIV seronegative patients were compared with 6 HIV seropositive patients. The HIV positive group included a higher proportion of males and a significantly greater history of prior treatment for condyloma. There was no difference in the median radiation dose (5020 cGy vs 4500 cGy, P = 0.10). There was a trend towards higher local tumour recurrence in the HIV seropositive patients although this was not statistically significant (30% vs 66%). The CD4 count of HIV positive patients did not correlate either with their ability to complete the prescribed treatment regimen or with subsequent recurrence. Conclusion. Combined chemoradiation is feasible in HIV positive patients, however, local recurrence rates in HIV positive patients may be higher. Tolerance of this therapy in HIV seropositive patients or recurrence after therapy are not related to the patient's CD4 cell count.

KW - Anal carcinoma

KW - Anus

KW - Chemoradiation

KW - HIV

KW - HIV seropositive

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0035159779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035159779&partnerID=8YFLogxK

U2 - 10.1046/j.1463-1318.2001.00281.x

DO - 10.1046/j.1463-1318.2001.00281.x

M3 - Article

C2 - 12790938

AN - SCOPUS:0035159779

VL - 3

SP - 402

EP - 405

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 6

ER -